Description
Dasatinib is an anticancer chemotherapeutic compound that inhibits Abl, PDGFR, ephrin receptors, Src, c-Kit, and other Src-family kinases (LCK, HCK, FYN, and others). Dasatinib is clinically used to treat chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL); in acute myelogenous leukemia (AML) cells, dasatinib induces myeloid differentiation and autophagy. Dasatinib also displays antiviral activity, preventing dengue virus infection through its inhibition of FYN kinase.